Venrock’s VHCP Management’s Top Picks For 2016

Page 2 of 2

Anders Hove and Bong Koh decided not alter their investment in Heron Therapeutics Inc (NASDAQ:HRTX) during the last three months of 2015 and VHCP Management holds 1.09 million shares worth $29.2 million. Heron Therapeutics Inc (NASDAQ:HRTX) reported fourth quarter earnings earlier this month and missed Wall Street’s expectations. The company posted a loss of $0.87 per share, worse than analysts’ forecasts of a loss of $0.64 per share. For the whole Heron Therapeutics Inc (NASDAQ:HRTX)’s loss widened to $97.6 million or $2.95 a share. The stock is currently trading around the $18 level, down by 30% since the beginning of 2016.

Follow Heron Therapeutics Inc. (NASDAQ:HRTX)

DBV TECHNOLOGIES (OTCMKTS:DBVTF) is Hove and Koh’s new top dog, despite the fund having decreased its position by 34% over the quarter. In its latest 13F filing, VHCP Management has indicated ownership of 463,643 shares valued at $32.5 million. DBV TECHNOLOGIES (OTCMKTS:DBVTF) is a biotech company that focuses on treatments for severe allergies. Its portfolio comprises several products under the Viaskin® brand currently undergoing trials in various stages of development. DBV TECHNOLOGIES (OTCMKTS:DBVTF) is set to release its next earnings report on March 23 and analysts are expecting a loss of $0.53 per share.

Disclosure: none

Page 2 of 2